5:39 PM
 | 
Apr 30, 2013
 |  BC Extra  |  Company News

FDA approves Procysbi for nephropathic cystinosis

FDA approved an NDA from Raptor Pharmaceutical Corp. (NASDAQ:RPTP) for Procysbi ( RP103) to treat nephropathic cystinosis in patients aged six and...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >